Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease

Pretreatment With PCSK9 Inhibitor Protects the Brain Against Cardiac Ischemia/Reperfusion Injury Through a Reduction of Neuronal Inflammation and Amyloid Beta Aggregation

(2019) Nattayaporn Apaijai et al.   Journal of the American Heart Association

Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents

(2019) C Macchi et al.   European Journal of Preventive Cardiology

Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders

(2018) Massimiliano Ruscica et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages

(2018) Zufeng Ding et al.   CARDIOVASCULAR RESEARCH

PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer’s Disease

(2018) Hélène Courtemanche et al.   JOURNAL OF ALZHEIMERS DISEASE

Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease

(2018) Martine Paquette et al.   JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY

Hyperglycemia-Driven Neuroinflammation Compromises BBB Leading to Memory Loss in Both Diabetes Mellitus (DM) Type 1 and Type 2 Mouse Models

(2018) Slava Rom et al.   MOLECULAR NEUROBIOLOGY

Alterations in cholesterol metabolism–related genes in sporadic Alzheimer's disease

(2018) Cynthia Picard et al.   NEUROBIOLOGY OF AGING

PCSK9 induces a pro-inflammatory response in macrophages

(2018) Chiara Ricci et al.   Scientific Reports

Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates neuronal apoptosis following focal cerebral ischemia via apolipoprotein E receptor 2 downregulation in hyperlipidemic mice

(2018) Lei Wang et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

On the fluxes of side-chain oxidized oxysterols across blood-brain and blood-CSF barriers and origin of these steroids in CSF (Review)

(2018) Ingemar Björkhem et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Inhibiting PCSK9 — biology beyond LDL control

(2018) Robert M. Stoekenbroek et al.   Nature Reviews Endocrinology

No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data

(2017) Philip D Harvey et al.   EUROPEAN HEART JOURNAL

Integrated late onset Alzheimer's disease (LOAD) susceptibility genes: Cholesterol metabolism and trafficking perspectives

(2017) Hee Kim Dong et al.   GENE

Can LDL cholesterol be too low? Possible risks of extremely low levels

(2017) A. G. Olsson et al.   JOURNAL OF INTERNAL MEDICINE

Cellular cholesterol homeostasis and Alzheimer’s disease

(2017) Ta-Yuan Chang et al.   JOURNAL OF LIPID RESEARCH

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cognitive Function in a Randomized Trial of Evolocumab

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low LDL cholesterol,PCSK9andHMGCRgenetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study

(2017) Marianne Benn et al.   BMJ-British Medical Journal

Low LDL cholesterol,PCSK9andHMGCRgenetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study

(2017) Marianne Benn et al.   BMJ-British Medical Journal

Intracellular Cholesterol Trafficking and Impact in Neurodegeneration

(2017) Fabian Arenas et al.   Frontiers in Molecular Neuroscience

PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment

(2017) Matthew T. Mefford et al.   CIRCULATION

PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement

(2016) Nicola Ferri et al.   ATHEROSCLEROSIS

PCSK9 Association With Lipoprotein(a)Novelty and Significance

(2016) Hagai Tavori et al.   CIRCULATION RESEARCH

Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer’s Disease

(2016) Francesca Zimetti et al.   JOURNAL OF ALZHEIMERS DISEASE

The Complex Role of Apolipoprotein E in Alzheimer’s Disease: an Overview and Update

(2016) Laura Mahoney-Sanchez et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(−/−) mice may be associated with increased PCSK9 expression

(2016) Xue-Shan Zhao et al.   Molecular Medicine Reports

Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence

(2016) Nicola Ferri et al.   Translational Research

Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease

(2015) Liv Tybjærg Nordestgaard et al.   Alzheimers & Dementia

Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier

(2015) Steffen E. Storck et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease

(2015) Naoyuki Sato et al.   Frontiers in Aging Neuroscience

PCSK9 is Present in Human Cerebrospinal Fluid and is Maintained at Remarkably Constant Concentrations Throughout the Course of the Day

(2014) Yan Q. Chen et al.   LIPIDS

Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis

(2013) Hagai Tavori et al.   CIRCULATION RESEARCH

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

(2013) Jean-Charles Lambert et al.   NATURE GENETICS

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

(2013) Chia-Chen Liu et al.   Nature Reviews Neurology

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

(2013) Maryssa Canuel et al.   PLoS One

ApoE influences amyloid-  (A ) clearance despite minimal apoE/A  association in physiological conditions

(2013) P. B. Verghese et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cholesterol efflux is differentially regulated in neurons and astrocytes: Implications for brain cholesterol homeostasis

(2012) Jing Chen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Meta-analysis on association between the ATP-binding cassette transporter A1 gene (ABCA1) and Alzheimer's disease

(2012) Mei Jiang et al.   GENE

LRP1 expression in cerebral cortex, choroid plexus and meningeal blood vessels: Relationship to cerebral amyloid angiopathy and APOE status

(2012) Wan Adriyani W. Ruzali et al.   NEUROSCIENCE LETTERS

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

(2011) Nicola Ferri et al.   ATHEROSCLEROSIS

PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke

(2011) Estelle Rousselet et al.   JOURNAL OF LIPID RESEARCH

Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans

(2010) Lena Persson et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Cholesterol-related genes in Alzheimer's disease

(2010) M. Axel Wollmer   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Membrane rafts in Alzheimer's disease beta-amyloid production

(2010) Kulandaivelu S. Vetrivel et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk

(2010) Chandra A. Reynolds et al.   HUMAN MOLECULAR GENETICS

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain

(2010) Mali Liu et al.   JOURNAL OF LIPID RESEARCH

Amyloid Efflux Transporter Expression at the Blood-Brain Barrier Declines in Normal Aging

(2010) Gerald D. Silverberg et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

(2009) Mohammad Tabrizi et al.   AAPS Journal

Central nervous system: cholesterol turnover, brain development and neurodegeneration

(2009) John M. Dietschy   BIOLOGICAL CHEMISTRY

Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease

(2009) R. Deane et al.   CNS & Neurological Disorders-Drug Targets

Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation

(2009) Steve Poirier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer

(2009) Cameron R Stewart et al.   NATURE IMMUNOLOGY

Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy

(2009) Guojun Bu   NATURE REVIEWS NEUROSCIENCE

Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance

(2009) Jungsu Kim et al.   NEURON

Ablation of cholesterol biosynthesis in neural stem cells increases their VEGF expression and angiogenesis but causes neuron apoptosis

(2009) K. Saito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1

(2008) Mary Cabell Jonas et al.   EMBO REPORTS

Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease

(2008) Suzanne E. Wahrle et al.   JOURNAL OF CLINICAL INVESTIGATION

apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain

(2008) Rashid Deane et al.   JOURNAL OF CLINICAL INVESTIGATION